Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hana Biosciences, Inc |
---|---|
Information provided by: | Hana Biosciences, Inc |
ClinicalTrials.gov Identifier: | NCT00145041 |
The purpose of this study is to see how vincristine, when placed in an oil droplet called a liposome (VSLI), is absorbed, distributed (moved around) and excreted from the the body (pharmacokinetics). This study will also assess the safety of VSLI and to see if VSLI will slow the growth or shrink tumors in patients with metastatic melanoma that has resulted in liver impairment, and who have relapsed after previous therapies.
Condition | Intervention | Phase |
---|---|---|
Malignant Melanoma |
Drug: Vincristine Sulfate Liposomes Injection |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study |
Official Title: | An Evaluation of the Pharmacokinetic Profile of VSLI (Vincristine Sulfate Liposome Injection, 0.16 mg/mL) in Patients With Malignant Melanoma and Hepatic Dysfunction Secondary to Metastases |
Estimated Enrollment: | 8 |
Study Start Date: | February 2005 |
Study Completion Date: | November 2007 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Vincristine Sulfate Liposomes Injection
Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
|
OBJECTIVES:
Primary: To assess the pharmacokinetics of VSLI administered intravenously to patients with malignant melanoma and hepatic dysfunction secondary to metastases.
Secondary: To assess the safety and antitumor activity of VSLI in this population.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
University of Texas M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Agop Bedikian, MD | MD Anderson Cancer Center, Dept of Melanoma |
Study ID Numbers: | VSLI-12-HEPHARM |
Study First Received: | September 1, 2005 |
Last Updated: | December 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00145041 |
Health Authority: | United States: Food and Drug Administration |
Neuroectodermal Tumors Nevus, Pigmented Neoplasms, Germ Cell and Embryonal Neoplasm Metastasis Vincristine |
Neuroepithelioma Nevus Neuroendocrine Tumors Melanoma |
Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Mitosis Modulators |
Tubulin Modulators Neoplasms, Nerve Tissue Nevi and Melanomas Antimitotic Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions |